首頁 > 市場調查報告書 > 製藥 > 製藥企業 > 製藥產業的合作，授權，投資，收購與合併交易趨勢:2011年12月

聯絡我們?

市場調查報告書

製藥產業的合作，授權，投資，收購與合併交易趨勢:2011年12月

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011

出版商	GlobalData
出版日期	2011年12月	商品編碼	227183
內容資訊	英文 Pages: 69
價格	US $ 1000 PDF by E-mail (Single user license) US $ 2000 PDF by E-mail (Site license) US $ 3000 PDF by E-mail (Global license)

簡介
目錄
相關商品

製藥產業的合作，授權，投資，收購與合併交易趨勢:2011年12月 是由出版商GlobalData在2011年12月所出版的。這份英文市場調查報告書包含Pages: 69 價格從美金1000起跳。

簡介

本報告提供2011年11月的製藥產業的合作/授權交易，收購與合併，股票/債務發行，私募股權，創業融資相關詳細資訊，過去6個月的交易數和交易額的比較數據，依交易類型，治療領域，各地區詳細顯示，再加上前幾名財務顧問企業相關的資訊，為您概述為以下內容。

第1章目錄

第2章全球製藥/醫療市場交易摘要

交易分析:2011年11月
首位的交易:2011年11月
類型/交易數/各交易金額:2011年11月

第3章全球製藥/醫療市場各類型交易摘要

收購與合併:2011年11月
股票上市交易:2011年11月
債務發行交易:2011年11月
私募股權/風險企業投資交易:2011年11月

第4章全球製藥/醫療市場合作交易:2011年11月

合作交易:2011年11月
各治療領域合作交易:2011年6月-2011年11月
預付款/階段性付款，各交易金額的合作交易:2011年11月
各治療領域，預付款/階段性付款，各交易金額的合作交易:2011年6月-2011年11月
階段/交易數/各交易金額合作交易:2011年11月
不同階段，預付款/階段性付款，各交易金額的合作交易:2011年6月-2011年11月

第5章全球製藥/醫療市場授權契約:2011年11月

授權契約:2011年11月
預付款/階段性付款，各交易金額的授權契約交易:2011年11月
治療領域/各總交易金額的授權契約:2011年6月-2011年11月
治療領域/預付款/各階段性付款的授權契約交易:2011年6月-2011年11月
階段/各總交易金額的授權契約交易:2011年6月-2011年11月
階段/預付款/各階段性付款的授權契約交易:2011年6月-2011年11月

第6章全球製藥/醫療市場各治療領域交易摘要

腫瘤學交易:2011年11月
感染疾病交易:2011年11月
中央神經系統交易:2011年11月
代謝障礙交易:2011年11月
心臟血管系統交易:2011年11月
免疫疾病學交易:2011年11月
腸胃系統交易:2011年11月

第7章各地區交易摘要

北美的交易:2011年11月
歐洲的交易:2011年11月
亞太地區的交易:2011年11月
其他地區的交易:2011年11月

第8章全球製藥/醫療市場前幾名財務顧問

前幾名財務顧問的收購與合併:2011年6月-2011年11月
前幾名財務顧問的股票上市:2011年6月-2011年11月

第9章其他資訊

圖表

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Novemeber 2011. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.
Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
Analysis of partnership and licensing deals based on clinical stage of development of products.
Summary of the pharmaceutical deals globally in the last six months.
Information on the top deals happened in the pharmaceutical industry.
Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.
Find out the major deal performing segments for investments in your industry.
Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
Identify companies that are aggressively looking to raise capital in the market
Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
Identify growth segments and opportunities in each region within the industry.
Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 4
1.2 List of Figures 6

2 Pharmaceuticals & Healthcare, Global, Deal Summary, 8

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, November 2011 8
2.2 Pharmaceuticals & Healthcare, Global, Top Deals, November 2011 10

2.2.1 Gilead Sciences To Acquire Pharmasset For $11 Billion 10
2.2.2 Amgen Completes Public Offering Of Senior Notes For $6 Billion 10
2.2.3 Teva Pharmaceutical Completes Public Offering Of Senior Notes For $5 Billion 10
2.2.4 Express Scripts Completes Private Placement Of Senior Notes For $4.1 Billion 11
2.2.5 Lundbeck Enters Into Co-Development Agreement With Otsuka Pharmaceutical 11

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Values, November 2011 12

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 13

3.1 Pharmaceuticals & Healthcare, Global, M&A, November 2011 13

3.1.1 Top M&A Deals in November 2011 14
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, June 2011-November 2011 15

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, November 2011 16

3.2.1 Top Equity Offering Deals in November 2011 17
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, June 2011 - November 2011 18

3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, November 2011 19

3.3.1 Top Debt Offering Deals in November 2011 20
3.3.2 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, June 2011 - November 2011 21

3.4 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, November 2011 22

3.4.1 Top PE/VC Deals in November 2011 23
3.4.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, November 2011 24
3.4.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, November 2011 25
3.4.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2011 - November 2011 26
3.4.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2011 - November 2011 27

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, November 2011 28

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, November 2011 28
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, June 2011 - November 2011 29
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), November 2011 30

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, November 2011 31

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 32
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), June 2011 - November 2011 33
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 34

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2011 35

5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2011 35
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 36

5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, November 2011 37
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, September 2011 37
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, September 2011 38

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), June 2011 - November 2011 39
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), June 2011 - November 2011 40
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), June 2011 - November 2011 41
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), June 2011 - November 2011 42

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 43

6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, November 2011 43

6.1.1 Oncology - Deals of the Month 44

6.2 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, November 2011 46

6.2.1 Infectious Diseases - Deals of the Month 47

6.3 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, November 2011 48

6.3.1 Central Nervous System - Deals of the Month 49

6.4 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, November 2011 50

6.4.1 Metabolic Disorders - Deals of the Month 51

6.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, November 2011 52

6.5.1 Cardiovascular - Deals of the Month 53

6.6 Pharmaceuticals & Healthcare, Global, Immunology Deals, November 2011 54

6.6.1 Immunology - Deals of the Month 55

6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals, November 2011 56

6.7.1 Gastrointestinal - Deals of the Month 57

7 Deal Summary by Geography 58

7.1 Pharmaceuticals & Healthcare, North America Deals, November 2011 58

7.1.1 North America - Deals of the Month 59

7.2 Pharmaceuticals & Healthcare, Europe, Deals, November 2011 60

7.2.1 Europe - Deals of the Month 61

7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, November 2011 62

7.3.1 Asia-Pacific - Deals of the Month 63

7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, November 2011 64

7.4.1 Rest of the World - Deals of the Month 65

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 66

8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, June 2011 - November 2011 66
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, June 2011 - November 2011 67

9 Further Information 68

9.1 Methodology 68
9.2 About GlobalData 68
9.3 Contact Us 69
9.4 Disclosure information 69
9.5 Disclaimer 69

List of Tables

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 9
Table 2: Pharmaceuticals & Healthcare, Global, Top Deals, November 2011 10
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), November 2011 12
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 13
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, November 2011 14
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2011 - November 2011 15
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 16
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, November 2011 17
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 18
Table 10: Pharmaceuticals & Healthcare, Global, Debt Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 19
Table 11: Pharmaceuticals & Healthcare, Global, Top Debt Offering Deals, November 2011 20
Table 12: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal values (US$ m), June 2011 - November 2011 21
Table 13: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 22
Table 14: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, November 2011 23
Table 15: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, June 2011 - November 2011 24
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), November 2011 25
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 26
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2011 - November 2011 27
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 28
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 29
Table 21: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 30
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 31
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 32
Table 24: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2011 - November 2011 33
Table 25: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), June 2011 - November 2011 34
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 35
Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 36
Table 28: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Deal Value, November 2011 37
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, September 2011 37
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, September 2011 38
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal values (US$ m), June 2011 - November 2011 39
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), November 2011 40
Table 33: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, June 2011 - November 2011 41
Table 34: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2011 42
Table 35: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 44
Table 36: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 46
Table 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 48
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 51
Table 39: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 52
Table 40: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 54
Table 41: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 56
Table 42: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 59
Table 43: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 60
Table 44: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 62
Table 45: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 64
Table 46: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 66
Table 47: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 67

List of Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 8
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Values (%),November 2011 12
Figure 3: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 13
Figure 4: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2011 - November 2011 15
Figure 5: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 16
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 18
Figure 7: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 19
Figure 8: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 21
Figure 9: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 22
Figure 10: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2011 - November 2011 24
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%) and Deal Values (%), November 2011 25
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 26
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 28
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 29
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 30
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 32
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2011 - November 2011 33
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 34
Figure 19: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 35
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 36
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 39
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 40
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals and Deal Values (US$ m), June 2011 - November 2011 41
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), November 2011 42
Figure 25: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 43
Figure 26: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 46
Figure 27: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 48
Figure 28: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 50
Figure 29: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 52
Figure 30: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 54
Figure 31: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 56
Figure 32: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 58
Figure 33: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 60
Figure 34: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 62
Figure 35: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 64
Figure 36: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 66
Figure 37: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 67

簡介
目錄
相關商品

使用指南產品及服務須知網站導覽

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp

製藥產業的合作，授權，投資，收購與合併交易趨勢:2011年12月

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011